hSCRO Committee Meetings and Deadlines

The hSCRO Full Committee meets once a month and will review the following types of submissions:

  • All New research protocol submissions which require hSCRO review
  • Addition of new cell lines or materials as listed under “Activities that required hSCRO review” if materials are not from federally/state-funded established cell repositories and/or provenance documentation has not been previously reviewed by UCI hSCRO.
  • Modifications containing substantial changes to the specific aims or design of the study.
  • In vivo transplantation of pluripotent stem cells, cells of fetal origin or neural stem cells (with the exception of the addition of teratoma assays which qualify for expedited review).
  • HSCRO Full Committee meeting schedule (deadline for submission and corresponding meeting dates)

Deadline DateMeeting Date
December 7, 2022January 5, 2023
January 13, 2023February 2, 2023
February 10, 2023March 2, 2023
March 10, 2023April 6, 2023
April 14, 2023May 4, 2023
May 12, 2023June 1, 2023
June 16, 2023July 6, 2023
July 14, 2023August 3, 2023
August 18, 2023September 7, 2023
September 15, 2023October 5, 2023
October 13, 2023November 2, 2023
November 10, 2023December 7, 2023


Expedited review by the hSCRO Subcommittee is performed at weekly meetings. The following types of transactions qualify for expedited review:

  • Proposed changes in research related to activities that do not significantly affect the assessment of the ethical and social issues, and do not substantially change the specific aims or design of the study.
  • Addition of teratoma assay standard in vivo procedur
  • Continuing Review of research approved by the hSCRO Full unless the research has had any instance of noncompliance or unanticipated problems during the previous year of approval


Administrative review by hSCRO Committee designated staff is performed on a rolling basis for the following types of submissions:

  • Addition or deletion of personnel as long as key research personnel are not deleted from the study team.
  • Updates in study locations and cell storage locations.
  • Deletions of cell lines.
  • Additions of registered cell lines, cell lines/ materials that have been previously approved by UCI hSCRO or cell lines obtained from source material that has previously been verified by UCI hSCRO including standard fluorescent reporter lines (such as GFP). Note:  federally/state-funded cell established repositories (such as the NIH registry) are considered already verified sources.